WO2004019043A3 - Polypeptide biomarkers for diagnosing alzheimer's disease - Google Patents

Polypeptide biomarkers for diagnosing alzheimer's disease Download PDF

Info

Publication number
WO2004019043A3
WO2004019043A3 PCT/EP2003/008879 EP0308879W WO2004019043A3 WO 2004019043 A3 WO2004019043 A3 WO 2004019043A3 EP 0308879 W EP0308879 W EP 0308879W WO 2004019043 A3 WO2004019043 A3 WO 2004019043A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
diagnosing alzheimer
human
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008879
Other languages
French (fr)
Other versions
WO2004019043A2 (en
Inventor
Oezkan Yalkinoglu
Gerhard Koenig
Denis Francois Hochstrasser
Jean-Charles Sanchez
Odile Carrette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018283A external-priority patent/EP1394549A1/en
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to JP2004530120A priority Critical patent/JP4405919B2/en
Priority to DE60322719T priority patent/DE60322719D1/en
Priority to DK03792291T priority patent/DK1535076T3/en
Priority to US10/525,633 priority patent/US20060240561A1/en
Priority to EP03792291A priority patent/EP1535076B1/en
Priority to AU2003251702A priority patent/AU2003251702B2/en
Priority to CA2496321A priority patent/CA2496321C/en
Publication of WO2004019043A2 publication Critical patent/WO2004019043A2/en
Publication of WO2004019043A3 publication Critical patent/WO2004019043A3/en
Anticipated expiration legal-status Critical
Priority to AU2010212317A priority patent/AU2010212317B2/en
Priority to AU2010212316A priority patent/AU2010212316B2/en
Priority to US13/099,110 priority patent/US8772042B2/en
Priority to US14/217,716 priority patent/US20140194318A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific markers in body fluids (e.g. CSF), using mass spectrometric analysis (SELDI-TOF MS). The specific markers are: human cystatin C, human beta-2-microglobulin, human myoglobin neurosecretory protein VGF or fragments of these proteins.
PCT/EP2003/008879 2002-08-23 2003-08-11 Polypeptide biomarkers for diagnosing alzheimer's disease Ceased WO2004019043A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2004530120A JP4405919B2 (en) 2002-08-23 2003-08-11 Biomarkers for the diagnosis of Alzheimer's disease
DE60322719T DE60322719D1 (en) 2002-08-23 2003-08-11 POLYPEPTIDE BIOMARKERS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER
DK03792291T DK1535076T3 (en) 2002-08-23 2003-08-11 Polypeptide biomarkers for the diagnosis of Alzheimer's disease
US10/525,633 US20060240561A1 (en) 2002-08-23 2003-08-11 Biomarkers for diagnosing alzheimer's disease
EP03792291A EP1535076B1 (en) 2002-08-23 2003-08-11 Polypeptide biomarkers for diagnosing alzheimer's disease
AU2003251702A AU2003251702B2 (en) 2002-08-23 2003-08-11 Polypeptide biomarkers for diagnosing alzheimer's disease
CA2496321A CA2496321C (en) 2002-08-23 2003-08-11 Biomarkers for diagnosing alzheimer's disease
AU2010212316A AU2010212316B2 (en) 2002-08-23 2010-08-12 Polypeptide Biomarkers for diagnosing Alzheimer's disease
AU2010212317A AU2010212317B2 (en) 2002-08-23 2010-08-12 Polypeptide Biomarkers for diagnosing Alzheimer's disease
US13/099,110 US8772042B2 (en) 2002-08-23 2011-05-02 Biomarkers for diagnosing alzheimer's disease
US14/217,716 US20140194318A1 (en) 2002-08-23 2014-03-18 Biomarkers for diagnosing alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02018283A EP1394549A1 (en) 2002-08-23 2002-08-23 Biomarkers for diagnosing Alzheimer's disease
EP02018283.8 2002-08-23
EP02026643 2002-11-29
EP02026643.3 2002-11-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/525,633 A-371-Of-International US20060240561A1 (en) 2002-08-23 2003-08-11 Biomarkers for diagnosing alzheimer's disease
US13/099,110 Continuation US8772042B2 (en) 2002-08-23 2011-05-02 Biomarkers for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2004019043A2 WO2004019043A2 (en) 2004-03-04
WO2004019043A3 true WO2004019043A3 (en) 2004-06-24

Family

ID=31947886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008879 Ceased WO2004019043A2 (en) 2002-08-23 2003-08-11 Polypeptide biomarkers for diagnosing alzheimer's disease

Country Status (10)

Country Link
EP (3) EP1953556B1 (en)
JP (1) JP4405919B2 (en)
AT (2) ATE475888T1 (en)
AU (3) AU2003251702B2 (en)
CA (6) CA2745724C (en)
DE (2) DE60333608D1 (en)
DK (3) DK1953556T3 (en)
ES (3) ES2347924T3 (en)
PT (1) PT1535076E (en)
WO (1) WO2004019043A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469312A1 (en) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
GB0502068D0 (en) 2005-02-01 2005-03-09 King S College London Screening method
EP1869473A2 (en) * 2005-04-06 2007-12-26 mosaiques diagnostics and therapeutics AG Polypeptide marker for diagnosing alzheimer's disease
ATE511643T1 (en) * 2005-06-16 2011-06-15 Vermillion Inc FRAGMENT OF THE NEUROSECRETORIC PROTEIN VGF AS A BIOMARRKER FOR ALZHEIMER'S DISEASE
CA2689848A1 (en) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
WO2007106466A2 (en) * 2006-03-11 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Beta-2 microglobulin as a biomarker for peripheral artery disease
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
CA2718955C (en) 2008-03-21 2015-10-13 Manuela G. Neuman Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
AU2009295357A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
JP2010271078A (en) 2009-05-19 2010-12-02 Mcbi:Kk Biomarker for mental illness including cognitive dysfunction disease and method for detecting mental illness including cognitive dysfunction disease using the biomarker
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US10688130B2 (en) 2013-12-09 2020-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
CA2989138C (en) 2015-06-15 2022-11-22 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating cognitive impairment or decline comprising tissue inhibitor of mettaloproteinase-2 (timp-2)
KR102572009B1 (en) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 Biomarker composition for diagnosing neurodegenerative diseases comprising Cystatin C, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
EP1266225A2 (en) * 2000-03-20 2002-12-18 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of breast cancer
EP1325338A2 (en) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
CA2446886A1 (en) * 2001-04-06 2002-10-17 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
EP1408333A3 (en) * 2001-10-03 2006-10-25 Pfizer Products Inc. Diagnosis and treatment of Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2003 (2003-03-01), CARRETTE ODILE ET AL: "A new sensitive and highly specific test for the diagnosis of Alzheimer disease using the ProteinChip(R) technology.", XP002265308, Database accession no. PREV200300358956 *
FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03-01), FASEB Meeting on Experimental Biology: Translating the Genome;San Diego, CA, USA; April 11-15, 2003, pages Abstract No. 80.3, ISSN: 0892-6638 (ISSN print) *
UTAL A ET AL: "Preliminary expression analysis in Alzheimer's disease using SELDI protein chips.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 83.7, XP000989844, ISSN: 0190-5295 *
WEI, LIHONG ET AL: "Cystatin C: Icelandic-like mutation in an animal model of cerebrovascular.beta.-amyloidosis", STROKE (DALLAS) (1996), 27(11), 2080-2085, XP000998699 *

Also Published As

Publication number Publication date
CA2745569C (en) 2015-07-14
CA2745998A1 (en) 2004-03-04
ATE475888T1 (en) 2010-08-15
AU2010212316B2 (en) 2012-05-24
DK1953556T3 (en) 2010-10-25
ATE403875T1 (en) 2008-08-15
CA2496321C (en) 2013-05-21
CA2745731A1 (en) 2004-03-04
CA2746000A1 (en) 2004-03-04
WO2004019043A2 (en) 2004-03-04
JP4405919B2 (en) 2010-01-27
EP1535076B1 (en) 2008-08-06
AU2010212316A1 (en) 2010-09-09
CA2745998C (en) 2013-11-26
DE60322719D1 (en) 2008-09-18
DK2221620T3 (en) 2014-01-06
EP1953556B1 (en) 2010-07-28
AU2003251702B2 (en) 2010-06-03
PT1535076E (en) 2008-11-03
EP1953556A2 (en) 2008-08-06
CA2745724A1 (en) 2004-03-04
CA2745724C (en) 2015-06-02
CA2745569A1 (en) 2004-03-04
AU2010212317A1 (en) 2010-09-09
CA2496321E (en) 2004-03-04
EP2221620A3 (en) 2010-11-24
EP2221620A2 (en) 2010-08-25
EP1535076A2 (en) 2005-06-01
DE60333608D1 (en) 2010-09-09
AU2003251702A1 (en) 2004-03-11
EP1953556A3 (en) 2008-11-26
DK1535076T3 (en) 2008-11-24
ES2311751T3 (en) 2009-02-16
CA2496321A1 (en) 2004-03-04
ES2436318T3 (en) 2013-12-30
EP2221620B1 (en) 2013-10-02
JP2005536729A (en) 2005-12-02
CA2745731C (en) 2015-05-12
CA2746000C (en) 2014-10-21
ES2347924T3 (en) 2010-11-25
AU2010212317B2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2004019043A3 (en) Polypeptide biomarkers for diagnosing alzheimer's disease
WO2003070894A3 (en) A non-invasive diagnostic test utilizing histone modification markers
EP0391714A3 (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2006116351A3 (en) Method for the early detection of renal disease using proteomics
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
EP2251695A3 (en) Markers associated with endometrial disease
WO1999060017A3 (en) Human tumour-derived polypeptide hormone phosphatonin
WO2002008260A3 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
WO2001098539A3 (en) Gene markers for lung cancer
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
JP4452715B2 (en) Methods of using specific peptides as indicators of autism
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
WO2005003299A3 (en) Polynucleotides encoding novel guanylate binding proteins (gbp's)
WO2003083076A3 (en) Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, bgs5g and bgs5i
WO2004113566A3 (en) Disease related protein network
WO2007062363A3 (en) Method for diagnosing a person having sjogren's syndrome
WO2004045364A3 (en) Methods of detecting ovarian neoplasia
IL155687A0 (en) Polynucleotides encoding hlrrsi1 polypeptides
WO2002068587A3 (en) Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3
WO2002040539A3 (en) Gpcr-like protein and nucleic acids encoding same
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
WO2002066601A3 (en) Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam2
WO2002077639A3 (en) Osteocalcin fragments assay to monitor bone resorption
WO2000042165A3 (en) Bone marrow-specific protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003792291

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2496321

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003251702

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004530120

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003792291

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006240561

Country of ref document: US

Ref document number: 10525633

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10525633

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003792291

Country of ref document: EP